Related Experiment Video

Updated: Oct 19, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Hepatic Interactions in Atherosclerotic Heart Disease

Naga Venkata K Pothineni1, Yogita Rochlani1, Swathi Subramany1

  • 1Division of Cardiology, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

The American Journal of the Medical Sciences
|September 21, 2021
PubMed

Insights

Atherosclerotic heart disease involves chronic inflammation affecting multiple organs. This review explores the liver

Area of Science:

  • Cardiovascular Medicine
  • Hepatology
  • Inflammation Biology

Background:

  • Atherosclerotic heart disease is a leading cause of death globally.
  • Chronic inflammation is increasingly recognized as a key mediator in atherosclerosis.
  • The heart and vasculature are primary targets, but atherosclerosis triggers systemic responses impacting other organs.

Purpose of the Study:

  • To review the intricate relationship between the liver and the heart in myocardial ischemia.
  • To describe epidemiological links between liver diseases and coronary heart disease.
  • To discuss clinical management challenges for patients with co-existing heart and liver conditions.

Main Methods:

  • Literature review focusing on cardiovascular and hepatology research.
  • Analysis of epidemiological data on heart and liver disease co-morbidity.
  • Synthesis of current understanding of pathophysiological mechanisms.

Main Results:

  • The liver plays a crucial role in systemic hemostasis and responds to atherosclerosis and myocardial ischemia.
  • Established pathophysiological links exist between systemic liver diseases and heart disease.
  • Significant epidemiological associations are observed between various liver pathologies and coronary heart disease.

Conclusions:

  • The liver is integral to the systemic response to atherosclerosis and myocardial ischemia.
  • Understanding the heart-liver axis has significant therapeutic implications.
  • Integrated clinical management is essential for patients with concurrent coronary heart disease and hepatic abnormalities.

More Related Videos

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.4K
Quantification of Atherosclerosis in Mice06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

38.8K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
27
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
67
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
31
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
33
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
185
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
26